BullishAgent BullishAgent Filings Market Economic Earnings Ratings IPOs ETFs Insiders Institutional Funds Screener
Sign in Register

XRTX

XORTX Therapeutics Inc. NASDAQ Listed Sep 23, 2021
Healthcare ·Biotechnology ·CA · xortx.com
$2.65
Pre-mkt $2.41 -0.75%
Mkt Cap $737,996
52w Low $1.73 17.4% of range 52w High $7.05
50d MA $2.31 200d MA $3.11
P/E (TTM) -0.1x
EV/EBITDA 0.1x
P/B 0.2x
Debt/Equity 0.0x
ROE
P/FCF -0.2x
RSI (14)
ATR (14)
Beta 0.09
50d MA $2.31
200d MA $3.11
Avg Volume 1.3M
XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.
SIC Code
2834
CIK (SEC)
Phone
+1 403 455 7727
421 – 7th Avenue SW · Vancouver, BC T2P 4K9 · CA
Data updated apr 27, 2026 10:54am · Source: massive.com